Genetic Testing Market Introduction and Overview
According to SPER Market Research, the Global Genetic Testing Market is estimated to reach USD 92.58 billion by 2034 with a CAGR of 22.71%.
The report includes an in-depth analysis of the Global Genetic Testing Market, including market size and trends, product mix, Applications, and supplier analysis. The global genetic testing market was valued at USD 11.96 billion in 2024 and is expected to increase at a CAGR of 22.71% from 2025 to 2034. This market's growth is primarily driven by government initiatives promoting genetic testing, the rising prevalence of genetic disorders, the growing need for early disease detection and prevention, the expanding applications of genetic testing in oncology, and the falling costs of sequencing procedures. However, the high cost of genetic testing in low-income countries, as well as the social and ethical concerns of genetic testing, limit the market's growth potential.
By Offering Insights: In 2024, the genetic testing market will be divided into consumables & reagents, instruments, and services. The consumables & reagents segment is expected to have the largest share. This is due to the ongoing need for reagents and kits, new product launches, and the growing demand for clinical diagnostic tests such as prenatal testing and newborn screening.
By Test Insights: In 2024, the prenatal testing segment is expected to make up the largest part of the genetic testing market. The market is divided into several types of tests: prenatal testing, predictive and presymptomatic testing, diagnostic testing, carrier testing, newborn screening, and preimplantation testing. Prenatal testing checks for fetal abnormalities related to genetic disorders, making it the best method to assess the genetic risks for an infant's health. Its use is growing quickly in both developed and developing countries.
By Method Insights: In 2024, the molecular tests segment is expected to have the largest share of the genetic testing market. The market is divided into molecular tests, chromosomal tests, and biochemical tests. Molecular tests include different methods like targeted single variant, single gene, gene panel, and whole exome or whole genome sequencing. The growth of this segment is due to technological advancements that allow for cheaper, faster, and highly accurate sequencing using whole genome sequencing (WGS) and whole exome sequencing (WES) technology.
By End User Insights: In 2024, the largest share of the genetic testing market is expected to come from the hospitals and clinics segment. This segment's significant market share is due to more advanced sequencing technologies being used in hospitals and a growing use of genetic tests for detecting, diagnosing, and treating both rare and common diseases worldwide.
Regional Insights: Asia-Pacific is expected to have the fastest growth rate in the genetic testing market over the forecast period. The Asia-Pacific region's growth is being driven by the region's improving healthcare infrastructure, a huge patient pool, the expanding acceptance of advanced genomics technology, the rising prevalence of numerous chronic diseases, and the increasing affordability of genomic testing.
Market Competitive Landscape:
The global genetic testing industry is very competitive, with many companies working hard to lead the market through innovation, diverse products, and smart investments. These companies have large product ranges, a wide presence, and strong distribution networks to meet various customer needs in clinical and direct-to-consumer markets. To stay ahead, many leaders invest heavily in research and development, leading to advanced genetic testing solutions. This focus not only strengthens their market position but also supports the industry's evolution to meet demands for personalized medicine and disease detection. For example, in June 2023, Devyser launched LynchFAP and BRCA PALB2 for Lynch syndrome diagnosis and cancers.
Recent Developments:
- EpiMedTech announced the debut of epiGeneComplete in October 2024, a comprehensive profile test that provides insight into aging, metabolism difficulties, inflammation, stress, and other factors. The test employs an NGS technology as well as DNA methylation and SNP markers to improve accuracy.
- ProPhase Labs, Inc announced in November 2024 that DNA Complete, Inc will be a wholly owned subsidiary delivering direct-to-consumer DNA tests.
- In March 2024, the genetic testing and analysis business Nucleus Genomics announced the introduction of a whole-genome sequencing test to provide its clients the advantages of personalized treatment.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Offering, By Test Type, By Method, By End User. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Illumina, Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, OPKO Health Inc, Natera, Inc, PerkinElmer, Inc, Myriad Genetics, Inc, Centogene N.V, Konica Minolta, Inc, Fulgent Genetics, Inc. |
Key Topics Covered in the Report:
- Global Genetic Testing Market Size (FY’2021-FY’2034)
- Overview of Global Genetic Testing Market
- Segmentation of Global Genetic Testing Market By Offering (Consumables, Reagents, Instruments, Services)
- Segmentation of Global Genetic Testing Market By Test Type (Diagnostic, Prenatal, Carrier, Newborn, Preimplantation)
- Segmentation of Global Genetic Testing Market By Method (Molecular, Chromosomal)
- Segmentation of Global Genetic Testing Market By End User (Hospitals, Diagnostic Laboratories)
- Statistical Snap of Global Genetic Testing Market
- Expansion Analysis of Global Genetic Testing Market
- Problems and Obstacles in Global Genetic Testing Market
- Competitive Landscape in the Global Genetic Testing Market
- Details on Current Investment in Global Genetic Testing Market
- Competitive Analysis of Global Genetic Testing Market
- Prominent Players in the Global Genetic Testing Market
- SWOT Analysis of Global Genetic Testing Market
- Globa Genetic Testing Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Genetic Testing Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Genetic Testing Market
7. Global Genetic Testing Market, By Offering (USD Million) 2021-2034
7.1. Consumables
7.2. Reagents
7.3. Instruments
7.4. Services
8. Global Genetic Testing Market, By Test Type (USD Million) 2021-2034
8.1. Diagnostic
8.2. Prenatal
8.3. Carrier
8.4. Newborn
8.5. Preimplantation
9. Global Genetic Testing Market, By Method (USD Million) 2021-2034
9.1. Molecular
9.2. Chromosomal
10. Global Genetic Testing Market, By End User (USD Million) 2021-2034
10.1. Hospitals
10.2. Diagnostic Laboratories
11. Global Genetic Testing Market, (USD Million) 2021-2034
11.1. Global Genetic Testing Market Size and Market Share
12. Global Genetic Testing Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Illumina, Inc
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Thermo Fisher Scientific Inc
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. F. Hoffmann-La Roche Ltd
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. OPKO Health Inc
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Natera, Inc
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. PerkinElmer, Inc
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Myriad Genetics, Inc
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Centogene N.V
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Konica Minolta, Inc
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Fulgent Genetics, Inc
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links